A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants

Study acronym: ROXI-DAISEN
StatusNot Yet Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study First Submitted
153 trials monitored
See 14 trials at risk
3,537 trials monitored
See 161 trials at risk
This study will test an experimental Regeneron drug called cenvacibart (REGN7508) ("study drug") compared with a placebo (a look-alike treatment with no active medicine) on top of background antiplatelet medications. The purpose of this study is to find out if cenvacibart can safely reduce the risk of another ischemic stroke or another blood clot related events in people who have recently had an ischemic stroke or mini-stroke (TIA). The study is looking at: * How well cenvacibart works * What side effects cenvacibart might cause * How much cenvacibart is in the blood at different times * How the body reacts to cenvacibart * How cenvacibart could affect the blood which can help researchers understand why cenvacibart works better in some people than others
Trial Details
NCT Number NCT07876492
Lead Sponsor Regeneron Pharmaceuticals
Conditions
(from sponsor)
Secondary Stroke
Related terms Ischemic Stroke, Stroke
Enrollment 6,106 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov